OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico

BATON ROUGE, LA--(Marketwired - August 03, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, today announces the submission of an application to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Mexico's equivalent of the U.S. Food and Drug Administration, seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company (the "License Partner"). The License Partner has granted OncBioMune an exclusive license for the anti-rabies drug for the Mexican market. The License Partner and product brand are being kept confidential for competitive reasons at this time.

The injectable anti-rabies immunoglobulin (human) is currently sold throughout the world, including Brazil, Argentina, Colombia and Peru. It is indicated for passive, transient post-exposure prophylaxis against rabies infection administered after exposure / contact with an animal suspected of being infected with rabies, a viral infection caused by viruses belonging to the Lyssavirus genus. The treatment has yet to be commercialized in Mexico.

"This is a popular anti-rabies therapeutic throughout South America and we are excited with the submission seeking to commercialize it in Mexico under the OncBioMune umbrella," commented Manuel Cosme Odabachian, General Manager of Global Operations at OncBioMune. "Rabies prevalence in Mexico is quite high and we believe that we will able to be competitive in the bid/tender process to capture our fair share of market. We are optimistic that we will be selling the product in 2018 and estimate annual demand in the range of 10,000 to 20,000 units, making it a strong complement to our other revenue-generating assets."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information:

OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer